Bimzelx gets FDA acceptance for resubmission

[Fred]

Update:

Quote:

---

UCB today announced that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under review with the U.S. Food & Drug Administration (FDA). UCB previously communicated the FDA action was expected in Q2, 2023. UCB now anticipates the FDA action in Q3, 2023. There are no open Information Requests from the FDA regarding the BLA for bimekizumab.

UCB is committed to ongoing collaboration with the FDA in order to bring bimekizumab to people in the U.S. living with moderate to severe plaque psoriasis as soon as possible.

Source: ucb.com